[This Week's IPO] Demand Forecasts and Subscription Schedule for the Third Week of March View original image

In the third week of this month (March), Hanpass, Medu, and Resens Medical will be accepting general subscriptions for their initial public offerings (IPOs).


<General Subscription>


◆Hanpass= The offering price has been set at the upper end of the desired price band, at 19,000 won. In the demand forecast, 2,229 domestic and foreign institutional investors participated, resulting in a competition ratio of 1,172.59 to 1. The general investor subscription for the IPO will take place from March 16 to 17, with the listing scheduled for March 25. The lead underwriters are Korea Investment & Securities and Daishin Securities.


Hanpass operates an integrated financial platform tailored for foreigners by combining wallet and payment features with its overseas remittance services. With the increasing number of foreign residents and the recovery of inbound tourism, demand for financial and consumer infrastructure for foreigners is expanding. The company explains that the growing user base is leading to increased transactions and revenue growth, establishing a platform-based growth model.


◆Medu= The offering price has been set at the upper end of the price band, at 21,600 won. In the demand forecast, 2,320 institutional investors participated, achieving a competition ratio of 1,108.93 to 1. The investor subscription will be held from March 16 to 17, and after completing the subscription process, the company plans to list on the KOSDAQ market on March 26. The lead underwriter is Shinhan Investment & Securities.


Medu's core competencies lie in its precision biosignal measurement technology and on-device machine learning-based biosignal processing technology. Leveraging these strengths, it has established the first commercial reference in the domestic mobile remote patient monitoring (aRPM) sector, pioneering the market based on real-world experience centered on clinical settings.


◆Resens Medical= The desired offering price band is between 9,000 and 11,000 won. The demand forecast was conducted until March 13, and the general subscription will be held over two days, from March 19 to 20. The lead underwriters are KB Securities and Korea Investment & Securities.



Founded in 2016, Resens Medical is a medical device company that has developed its own precision cooling technology to meet the unmet needs of clinical practice. Based on its technology that rapidly controls the temperature of cryogenic refrigerants to quickly lower target areas to the desired temperature, the company provides cooling solutions for a wide range of fields, including dermatology, ophthalmology, and veterinary medicine.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing